Cladribine, Low-Dose Cytarabine (LDAC), and Venetoclax (VEN) in Older/Unfit Acute Myeloid Leukemia (AML) Patients: A Single-Institution Experience

被引：0
|
作者：
Yohannan, Binoy [1 ]
Khan, Hina [1 ]
Cervoni-Curet, Frances [1 ]
Rios, Adan [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
AML; cladribine; low-dose cytarabine; older/unfit AML;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-100
引用
收藏
页码：S267 / S267
页数：1
相关论文
共 50 条
  • [1] Safety and Efficacy of Venetoclax (VEN) Plus Low-Dose Cytarabine (LDAC) in Treatment-Naive Patients (PTS) Aged ≥ 65 Years with Acute Myeloid Leukemia (AML)
    Wei, A. H.
    Strickland, S. A.
    Roboz, G. J.
    Hou, J-Z.
    Fiedler, W.
    Lin, T. L.
    Walter, R. B.
    Enjeti, A.
    Fakouhi, K. M.
    Darden, D. E.
    Dunbar, M.
    Agarwal, S.
    Salem, A. H.
    Mabry, M.
    Hayslip, J.
    ANNALS OF HEMATOLOGY, 2017, 96 : S85 - S85
  • [2] Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML)
    Kadia, Tapan M.
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Jain, Preetesh
    Jabbour, Elias
    Verstovsek, Srdan
    Pemmaraju, Naveen
    Faderl, Stefan
    Ravandi, Farhad
    Konopleva, Marina
    Tuttle, Carla
    Brandt, Mark
    Wang, Xuemei
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2013, 122 (21)
  • [3] Cladribine in the Treatment of Acute Myeloid Leukemia: A Single-Institution Experience
    Martin, Mike G.
    Welch, John S.
    Augustin, Kristan
    Hladnik, Lindsay
    DiPersio, John E.
    Abboud, Camille N.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (04): : 298 - 301
  • [4] Comparative Effectiveness of Combination Glasdegib plus Low-Dose Cytarabine (GLAS plus LDAC) Vs Combination Venetoclax plus Low-Dose Cytarabine (VEN plus LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods
    Westley, Tracy
    Forsythe, Anna
    Bell, Timothy J.
    Cappelleri, Joseph C.
    Chan, Geoffrey
    Tremblay, Gabriel
    BLOOD, 2018, 132
  • [5] Long-Term Follow-Up of a Phase 1/2 Study of Venetoclax (VEN) Plus Low-Dose Cytarabine (LDAC) in Previously Untreated Older Adults with Acute Myeloid Leukemia (AML)
    Wei, Andrew H.
    Strickland, Stephen
    Hou, Jing-Zhou
    Fiedler, Walter
    Lin, Tara L.
    Walter, Roland B.
    Hong, Wan-Jen
    Chyla, Brenda
    Jiang, Qi
    Popovic, Relja
    Hayslip, John
    Roboz, Gail J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S178 - S178
  • [6] VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IMPROVE THE REMISSION RATE IN OLDER OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
    Han, Xiao
    Song, Qingxiao
    Wan, Kai
    Zhang, Mengyun
    Liu, Xue
    Yan, Hongju
    Zhang, Cheng
    Wen, Qin
    Zhang, Xi
    BONE MARROW TRANSPLANTATION, 2024, 59 : 176 - 177
  • [7] Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)
    Kadia, Tapan
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Daver, Naval
    Jabbour, Elias
    Pemmaraju, Naveen
    Verstovsek, Srdan
    Burger, Jan A.
    Wierda, William G.
    Konopleva, Marina
    DiNardo, Courtney D.
    Jain, Nitin
    Brandt, Mark
    Tuttle, Carla
    Wang, Xuemei
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    BLOOD, 2014, 124 (21)
  • [8] Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience
    Heiblig, Mael
    Elhamri, Mohamed
    Tigaud, Isabelle
    Plesa, Adriana
    Barraco, Fiorenza
    Labussiere, Helene
    Ducastelle, Sophie
    Michallet, Mauricette
    Nicolini, Franck
    Plesa, Claudiu
    Wattel, Eric
    Salles, Gilles
    Thomas, Xavier
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2016, 8
  • [9] Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Reville, Patrick K.
    Kantarjian, Hagop
    Borthakur, Gautam
    Pemmaraju, Naveen
    DiNardo, Courtney D.
    Sasaki, Koji
    Daver, Naval
    Issa, Ghayas C.
    Ohanian, Maro
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Jain, Nitin
    Bhalla, Kapil N.
    Jabbour, Elias J.
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Rausch, Caitlin R.
    Malla, Rashmi
    Marek, Kelly
    Brandt, Mark
    Popat, Uday R.
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2021, 138
  • [10] Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)
    Huante, Emmanuel Almanza
    Kantarjian, Hagop
    Chien, Kelly S.
    DiNardo, Courtney D.
    Short, Nicholas
    Maiti, Abhishek
    Montalban-Bravo, Guillermo
    Daver, Naval
    Kawedia, Jitesh D.
    Bowie, Kayleigh
    Pierce, Sherry A.
    Ravandi, Farhad
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    BLOOD, 2022, 140 : 3344 - 3346
12345